In 1923, Salomon van Zwanenberg founded NV Organon in Oss, Netherlands, establishing a pharmaceutical company that would become synonymous with advances in women's health. The original Organon pioneered innovations in contraception and stood at the forefront of reproductive health for decades. Nearly a century later, in 2021, a new independent company called Organon emerged through a strategic spinoff from Merck (known as MSD outside the U.S. and Canada), carrying forward this rich legacy while forging a new path dedicated to the health of women worldwide.
Today, Organon operates as a global healthcare company with approximately 10,000 employees across nearly 60 countries, serving more than 140 markets with a diverse portfolio of over 60 medicines and devices. The company's mission centers on delivering impactful medicines and solutions for a healthier every day, with a focused strategy across three core business areas: Women's Health, Biosimilars, and Established Brands. By addressing health conditions that are unique to women, affect women disproportionately, or impact women differently - from contraception and fertility to cardiovascular disease and respiratory conditions - Organon envisions and actively works toward creating a better and healthier every day for every woman, recognizing that advancing women's health advances the health of society as a whole.